Revenio Group Oyj
Entity

  • Revenio Group Oyj

    Created in 2001
    Created in 1999
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    779 1,926

  • Activities

    healthtech

  • Technologies

    SaaS

  • Entity types

    SMB

  • Location

    Äyritie 22, 01510 Vantaa, Finland

    Vantaa

    Finland

  • Employees

    Scale: 201-500

    Estimated: 26

  • Engaged corporates

    1
    0 0

  • Added in Motherbase

    3 years, 5 months ago
Description
  • Value proposition

    [Automatic translation follows] Revenio is a global provider of comprehensive eye care diagnostic solutions.

    Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.

    In 2023, the Group's net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

    Revenio is a supplier of comprehensive eye care diagnostic solutions operating on the international market. The group offers fast, easy-to-use and reliable tools for diagnosing glaucoma, diabetic retinopathy and macular degeneration. Revenio Group's eye diagnostic solutions include intraocular pressure measuring devices (tonometers), fundus imaging devices, perimeters and clinical software under the iCare brand.

    The turnover of the Revenio group in 2023 was 96.6 million euros and the operating profit was 26.3 million euros. Revenio Group Oyj's shares are listed on Nasdaq Helsinki Oy under the trading symbol REG1V.

  • Original language

    Revenio is a global provider of comprehensive eye care diagnostic solutions.

    Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.

    In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

    Revenio on kansainvälisillä markkinoilla toimiva kokonaisvaltaisten silmien hoidon diagnostiikkaratkaisuiden toimittaja. Konserni tarjoaa nopeita, helppokäyttöisiä ja luotettavia työkaluja glaukooman, diabeettisen retinopatian ja silmänpohjan rappeuman diagnosointiin. Revenio-konsernin silmän diagnostiikkaratkaisuihin kuuluvat iCare-brändin alla silmänpaineen mittauslaitteet (tonometrit), silmänpohjan kuvantamislaitteet, perimetrit ja kliiniset ohjelmistot.

    Revenio-konsernin liikevaihto vuonna 2023 oli 96,6 miljoonaa euroa ja liiketulos 26,3 miljoonaa euroa. Revenio Group Oyj:n osake on listattu Nasdaq Helsinki Oy:ssä kaupankäyntitunnuksella REG1V.

Corporate interactions BETA
Corporate TypeTweets Articles
Nokia
Nokia
Telecoms, Telecommunications
Nokia
Telecoms, Telecommunications 		Other

17 Feb 2017


Similar entities
Last news
Show all articles
Social network dynamics